Does Everolimus Increase Donor-Specific HLA Antibodies in Kidney Transplant Recipients?
Authors:
Open Access
- 1 September 2012
- journal article
- Published by Elsevier in American Journal of Transplantation
- Vol. 12 (9) , 2561-2562
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Donor-Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney TransplantationAmerican Journal of Transplantation, 2012
- Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept StudyAmerican Journal of Transplantation, 2011
- Paradoxical Aspects of Rapamycin Immunobiology in TransplantationAmerican Journal of Transplantation, 2011
- Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trialThe Lancet, 2011
- A Systematic Review on Steroid Withdrawal Between 3 and 6 Months After Kidney TransplantationTransplantation, 2010
- Efficacy on Renal Function of Early Conversion from Cyclosporine to Sirolimus 3 Months After Renal Transplantation: Concept StudyAmerican Journal of Transplantation, 2009